Survival Results by the Prospectively Determined Clinical Staging for Locally Advanced Gastric Cancer: A Follow-Up Study of JCOG1302A.

Authors

Tsutomu Hayashi, Ryosuke Kato, Noriko Mitome, Rei Ogawa, Takeo Fukagawa, Hitoshi Katai, Souya Nunobe, Masanori Tokunaga, Etsuro Bando, Yuichi Ito, Takanobu Yamada, Takashi Nomura, Shigeto Makino, Takahiro Kinoshita, Hisashi Hara, Masaki Aizawa, Narikazu Boku, Yukinori Kurokawa, Masanori Terashima, Takaki Yoshikawa

Published in

Annals of gastroenterological surgery. Oct 06, 2026. Epub Oct 06, 2026.

Abstract

Long-term overall survival (OS) of gastric cancer stratified by the prospectively determined clinical stage remains unclear.
This is an ancillary study of JCOG1302A, a prospective observational study that evaluated the accuracy of clinical diagnosis of gastric cancer with cT2/T3/T4, cN0/N1/N2/N3, and M0. The cT diagnosis was comprehensively determined by upper gastrointestinal endoscopy and upper abdominal contrast CT scan with 1 or 5 mm slice thickness. Lymph nodes with a minor axis greater than 8 mm or a major axis greater than 10 mm were defined as positive for metastasis. This follow-up study evaluated OS in eligible patients from JCOG1302A.
Among 1 260 patients enrolled in JCOG1302A between July 2013 and November 2014, survival data of 1 176 were analyzed. With a median follow-up of 6.0 years for 821 surviving patients, the 5 year-OS was 82.1% (95% CI, 77.3-85.9) in cT2 (n = 319), 72.7% (68.2-76.6) in cT3 (n = 450), 60.0% (54.9-64.7) in cT4a (n = 401), and 40.0% (5.2-75.3) in cT4b (n = 6), while that was 78.0% (74.2-81.2) in cN0 (n = 559), 70.6% (65.4-75.2) in cN1 (n = 350), 59.1% (52.5-65.1) in cN2 (n = 241), and 28.4% (12.7-46.5) in cN3 (n = 26). When combined with cT and cN, 5y-OS was 83.5% (77.8-87.8) in cT2N0 (n = 226), 77.2% (71.0-82.2) in cT3N0 (n = 232), 66.8% (56.3-75.2) in cT4aN0 (n = 100), 78.7% (68.6-85.8) in cT2N(+) (n = 93), 68.0% (61.1-73.8) in cT3N(+) (n = 218), and 57.7% (51.7-63.2) in cT4aN(+) (n = 301).
Clinical T and N categories were associated with OS in locally advanced gastric cancer, providing prognostic information that may help identify higher-risk clinical subgroups.

PMID:
42840681
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.